Balyasny Asset Management LLC Vanda Pharmaceuticals Inc. Transaction History

Balyasny Asset Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$4.28 - $6.57 $628,577 - $964,896	146,864 Added 1427.39%	157,153 $678,000
Q2 2023 Aug 14, 2023	BUY	$5.9 - $6.95 $60,705 - $71,508	10,289 New	10,289 $67,000
Q4 2022 Feb 14, 2023	BUY	$6.87 - $10.96 $205,893 - $328,471	29,970 Added 296.2%	40,088 $296,000
Q3 2022 Nov 14, 2022	BUY	$9.44 - $11.76 $95,513 - $118,987	10,118 New	10,118 $100,000
Q3 2019 Nov 14, 2019	SELL	$12.27 - $15.79 $247,817 - $318,910	-20,197 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$13.37 - $18.85 $270,033 - $380,713	20,197 New	20,197 $285,000
Q2 2018 Aug 14, 2018	SELL	$13.95 - $19.15 $343,407 - $471,415	-24,617 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$14.05 - $20.2 $198,343 - $285,163	14,117 Added 134.45%	24,617 $415,000
Q4 2017 Feb 14, 2018	SELL	$12.85 - $18.1 $146,490 - $206,340	-11,400 Reduced 52.05%	10,500 $160,000
Q3 2017 Nov 14, 2017	BUY	$15.4 - $18.85 $337,260 - $412,815	21,900	21,900 $392,000

156

44.7M

167K

33.6K

Ticker VNDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,561,500
Market Cap $271M
Description
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.